A phase 2 study of idelalisib plus rituximab in treatment-na¨ ı ve older patients with chronic lymphocytic leukemia
暂无分享,去创建一个
A. Zelenetz | I. Flinn | M. Keating | S. O'brien | J. Burger | L. Miller | S. Coutre | S. Mitra | Yeonhee Kim | N. Lamanna | T. Kipps | A. Yu | L. Holes | D. Johnson | R. Dansey | R. Dubowy
[1] R. Ulrich,et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.
[2] A. Zelenetz,et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. , 2014 .
[3] Xiao-Jie Yan,et al. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia , 2014, Leukemia and Lymphoma.
[4] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[5] A. Zelenetz,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.
[6] N. Chiorazzi,et al. B cell receptor signaling in chronic lymphocytic leukemia. , 2013, Trends in immunology.
[7] A. Johnson,et al. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] M. Davids,et al. Targeting the B cell receptor pathway in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.
[9] J. Reuben,et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. , 2011, Blood.
[10] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Hallek,et al. Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia , 2011, Drugs & aging.
[12] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.
[13] R. Ulrich,et al. Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies , 2010 .
[14] A. Sepulveda,et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. , 2010, Gastroenterology.
[15] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jeffrey A Jones,et al. Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .
[17] M. Hallek,et al. Treatment of elderly patients with chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.
[18] J. Dayer,et al. Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions. , 2008, Molecular immunology.
[19] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[20] G. Jenkins,et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia , 2008, Leukemia & lymphoma.
[21] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[22] C. Pashos,et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. , 2004, European journal of cancer care.
[23] J. Hainsworth,et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Okkenhaug,et al. PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.
[25] K. Okkenhaug,et al. Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.
[26] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[27] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Czuczman,et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[30] A. Polliack,et al. Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. , 2012, Blood reviews.